Hemochromatosis and iron overload: From bench to clinic

American Journal of the Medical Sciences

Volumn 346, Issue 5, 2013, Pages 403-412

  Barton, James C ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Arthropathy; Cirrhosis; Diabetes; Hemochromatosis; Hepcidin; HFE; Iron

Indexed keywords

ASCORBIC ACID; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; DOXYCYCLINE; HEMOGLOBIN; HEPCIDIN; IMMUNOGLOBULIN; IRON; NONHEME IRON PROTEIN;

CONFERENCE PAPER; GENE; HEMOCHROMATOSIS; HERITABILITY; HFE GENE; HUMAN; IRON OVERLOAD; JOINT; LIVER; MEAN CORPUSCULAR VOLUME; ORGAN INJURY; PANCREAS; PHLEBOTOMY; TISSUE INJURY; VIBRIO VULNIFICUS; VIBRIO VULNIFICUS INFECTION;

EID: 84887261602     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000192     Document Type: Conference Paper

References (101)

1. Stahl GE. Experimenta, observationes, animadversiones. Chymicae et Physicae (Berlin) 1731;CCC Numero:281-3.
2. Virchow R. Die patholgischen pigmente. Arch Pathol Anat 1847;1: 379-486.
3. Perls M. Nachweis von eisenoxyd in gewissen pigmenten. Virchow Arch Pathol Anat 1867;39:42-8.
4. Scheuer PJ, Williams R, Muir AR. Hepatic pathology in relatives of patients with haemochromatosis. J Pathol Bacteriol 1962;84:53-64.
5. Trousseau A. Glycosurie, Diabète Sucré. Clinique Médical de l'Hôtel- Dieu de Paris. 2nd edition, vol.2 Baillière, Paris. 1865; 663-98.
6. Troisier M. Diabète sucré. Bull Soc Anat Paris 1871;16:231-5.
7. von Recklinghausen FD. Über hämochromatose. Tagebl Versamml Natur Ärtze Heidelberg 1889;62:324-5.
8. Bezançon F, de Gennes L, Delarue J, et al. Cirrhose pigmentaire avec infantilisme et insuffisance cardiaque et aplasie endocriniennes multiples. Bull Mém Soc Med Hôp Paris 1932;48:967-74.
9. de Gennes L, Delarue J, de Vericourt R. Sur un nouveau cas de cirrhose pigmentaire avec infantilisme et myocarde. Le syndrome endocrine- hepato-cardiaque. Bull Mem Soc Méd Hôp Paris 1935;51:1228.
10. Sheldon JH. Haemochromatosis. London, England: Oxford University Press; 1935;1-382.
11. MacDonald RA. Hemochromatosis and Hemosiderosis. Springfield, Illinois: Charles C. Thomas; 1964;1-374.
12. Simon M, Pawlotsky Y, Bourel M, et al. Hémochromatose idiopathique: maladie associée a l'antigéne tissulaire HLA 3? Nouv Presse Med 1975;4:1432.
13. Cartwright GE, Edwards CQ, Kravitz K, et al. Hereditary hemochromatosis. Phenotypic expression of the disease. N Engl J Med 1979;301:175-9.
14. Edwards CQ, Griffen LM, Goldgar D, et al. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988;318:1355-62.
15. de Sousa M, Reimao R, LaCerda R, et al. Iron overload in beta 2- microglobulin-deficient mice. Immunol Lett 1994;39:105-11.
16. Santos M, Schilham MW, Rademakers LH, et al. Defective iron homeostasis in beta 2-microglobulin knockout mice recapitulates hereditary hemochromatosis in man. J Exp Med 1996;184:1975-85.
17. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
18. Krause A, Neitz S, Magert HJ, et al. LEAP-1, a novel highly disulfide- bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480:147-50.
19. Park CH, Valore EV, Waring AJ, et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-10.
20. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276:7811-9.
21. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102:783-8.
22. Parkkila S, Waheed A, Britton RS, et al. Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci U S A 1997;94: 13198-202.
23. Parkkila S, Parkkila AK, Waheed A, et al. Cell surface expression of HFE protein in epithelial cells, macrophages, and monocytes. Haematologica 2000;85:340-5.
24. Feder JN, Tsuchihashi Z, Irrinki A, et al. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 1997;272:14025-8.
25. Corradini E, Garuti C, Montosi G, et al. Bone morphogenetic protein signaling is impaired in an HFE knockout mouse model of hemochromatosis. Gastroenterology 2009;137:1489-97.
26. Barton JC, Acton RT. HLA-A and -B alleles and haplotypes in hemochromatosis probands with HFE C282Y homozygosity in central Alabama. BMC Med Genet 2002;3:9.
27. Ryan E, O'Keane C, Crowe J. Hemochromatosis in Ireland and HFE. Blood Cells Mol Dis 1998;24:428-32.
28. Asberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001;36:1108-15.
29. Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24.
30. Gurrin LC, Osborne NJ, Constantine CC, et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology 2008;135:1945-52.
31. Acton RT, Barton JC, Snively BM, et al. Geographic and racial/ethnic differences in HFE mutation frequencies in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Ethn Dis 2006;16:815-21.
32. Jouanolle AM, Fergelot P, Raoul ML, et al. Prevalence of the C282Y mutation in Brittany: penetrance of genetic hemochromatosis? Ann Genet 1998;41:195-8.
33. Beutler E, Felitti V, Gelbart T, et al. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000;133:329-37.
34. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005;352:1769-78.
35. Barton JC, Acton RT, Dawkins FW, et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in whites and blacks in the Hemochromatosis and Iron Overload Screening Study. Genet Test 2005;9:231-41.
36. Merryweather-Clarke AT, Pointon JJ, Shearman JD, et al. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997;34:275-8.
37. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program 2006;29-35:507.
38. Merryweather-Clarke AT, Cadet E, Bomford A, et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003;12:2241-7.
39. Barton JC, Edwards CQ, Phatak PD, et al. Classical and atypical HFE hemochromatosis. In: Barton JC, Edwards CQ, Phatak PD, et al, editors. Handbook of Iron Overload Disorders. Cambridge, England: Cambridge University Press; 2010. p. 127-48.
40. McLaren CE, Barton JC, Adams PC, et al. Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci 2003;325:53-62.
41. McLaren GD, McLaren CE, Adams PC, et al. Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. Can J Gastroenterol 2008;22:923-30.
42. Adams PC, Barton JC. How I treat hemochromatosis. Blood 2010; 116:317-25.
43. Barton JC, Edwards CQ, Phatak PD, et al. Iron toxicity. In: Barton JC, Edwards CQ, Phatak PD, et al, editors. Handbook of Iron Overload Disorders. Cambridge, England: Cambridge University Press; 2010. p. 28-33.
44. Deugnier YM, Charalambous P, le Quilleuc D, et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 1993;18:1363-9.
45. Deugnier YM, Guyader D, Crantock L, et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993;104:228-34.
46. Deugnier Y, Loréal O. Iron as a carcinogen. In: Barton JC, Edwards CQ, editors. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, England: Cambridge University Press; 2000. p. 239-49.
47. Hanot V, Schachmann M. Sur la cirrhose pigmentaire dans le diabète sucre. Arch Physiol Norm Pathol 1866;7:50-72.
48. Finch SC, Finch CA. Idiopathic hemochromatosis, an iron storage disease. Medicine (Baltimore) 1955;34:381-430.
49. Mirouze J, Schouker Y. Physionomie actuelle du diabète sucre au cours de l'hémochromatosis idiopathique. Presse Med 1967;45: 2245-50.
50. Rahier J, Loozen S, Goebbels RM, et al. The haemochromatotic human pancreas: a quantitative immunohistochemical and ultrastructural study. Diabetologia 1987;30:5-12.
51. Balcerzak SP, Mintz DH, Westerman MP. Diabetes mellitus and idiopathic hemochromatosis. Am J Med Sci 1968;255:53-62.
52. Dymock IW, Cassar J, Pyke DA, et al. Observations on the pathogenesis, complications and treatment of diabetes in 115 cases of haemochromatosis. Am J Med 1972;52:203-10.
53. McClain DA, Abraham D, Rogers J, et al. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia 2006;49:1661-9.
54. O'Sullivan EP, McDermott JH, Murphy MS, et al. Declining prevalence of diabetes mellitus in hereditary haemochromatosis\-The result of earlier diagnosis. Diabetes Res Clin Pract 2008;81:316-20.
55. Schumacher HR Jr. Hemochromatosis and arthritis. Arth Rheum 1964;7:41-50.
56. Ross JM, Kowalchuk RM, Shaulinsky J, et al. Association of heterozygous hemochromatosis C282Y gene mutation with hand osteoarthritis. J Rheumatol 2003;30:121-5.
57. Barton JC, Bertoli LF, Rothenberg BE. Peripheral blood erythrocyte parameters in hemochromatosis: evidence for increased erythrocyte hemoglobin content. J Lab Clin Med 2000;135:96-104.
58. McLaren CE, Barton JC, Gordeuk VR, et al. Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white HFE C282Y homozygotes in the hemochromatosis and iron overload screening study. Am J Hematol 2007;82:898-905.
59. Iliadou A, Evans DM, Zhu G, et al. Genomewide scans of red cell indices suggest linkage on chromosome 6q23. J Med Genet 2007;44: 24-30.
60. Barton JC, Patton MA, Edwards CQ, et al. Blood lead concentrations in hereditary hemochromatosis. J Lab Clin Med 1994;124:193-8.
61. Bressler JP, Olivi L, Cheong JH, et al. Divalent metal transporter 1 in lead and cadmium transport. Ann N Y Acad Sci 2004;1012:142-52.
62. Valberg LS, Ludwig J, Olatunbosun D. Alteration in cobalt absorption in patients with disorders of iron metabolism. Gastroenterology 1969;56:241-51.
63. Akesson A, Stal P, Vahter M. Phlebotomy increases cadmium uptake in hemochromatosis. Environ Health Perspect 2000;108:289-91.
64. Altstatt LB, Pollack S, Feldman MH, et al. Liver manganese in hemochromatosis. Proc Soc Exp Biol Med 1967;124:353-5.
65. Adams PC, Bradley C, Frei JV. Hepatic zinc in hemochromatosis. Clin Invest Med 1991;14:16-20.
66. Barton JC, Bertoli LF, Acton RT. Common variable immunodeficiency and IgG subclass deficiency in central Alabama hemochromatosis probands homozygous for HFE C282Y. Blood Cells Mol Dis 2003;31:102-11.
67. Blake PA, Merson MH, Weaver RE, et al. Disease caused by a marine Vibrio. Clinical characteristics and epidemiology. N Engl J Med 1979;300:1-5.
68. Bullen JJ, Spalding PB, Ward CG, et al. Hemochromatosis, iron and septicemia caused by Vibrio vulnificus. Arch Intern Med 1991;151: 1606-9.
69. Bonner JR, Coker AS, Berryman CR, et al. Spectrum of Vibrio infections in a Gulf Coast community. Ann Intern Med 1983;99:464-9.
70. Muench KH. Hemochromatosis and infection: alcohol and iron, oysters and sepsis. Am J Med 1989;87:40N-3N.
71. Klontz KC, Lieb S, Schreiber M, et al. Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987. Ann Intern Med 1988;109:318-23.
72. Barton JC, Acton RT. Hemochromatosis and Vibrio vulnificus wound infections. J Clin Gastroenterol 2009;43:890-3.
73. MacSween RNM. Acute abdominal crises, circulatory collapse and sudden death in haemochromatosis. Q J Med 1966;35:389-98.
74. Christopher GW. Escherichia coli bacteremia, meningitis, and hemochromatosis. Arch Intern Med 1985;145:1908.
75. Corke PJ, McLean AS, Stewart D, et al. Overwhelming gram-negative septic shock in haemochromatosis. Anaesth Intensive Care 1995; 23:346-9.
76. Distante S, Robson KJ, Graham-Campbell J, et al. The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet 2004;115:269-79.
77. Butterworth JR, Cooper BT, Rosenberg WM, et al. The role of hemochromatosis susceptibility gene mutations in protecting against iron deficiency in celiac disease. Gastroenterology 2002;123:444-9.
78. Naugler C. Hemochromatosis: a Neolithic adaptation to cereal grain diets. Med Hypotheses 2008;70:691-2.
79. Beutler E. Iron absorption in carriers of the C282Y hemochromatosis mutation. Am J Clin Nutr 2004;80:799-800.
80. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003;33:21-2.
81. Roetto A, Totaro A, Cazzola M, et al. Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet 1999;64:1388-93.
82. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004;36:77-82.
83. Camaschella C, Roetto A, Cali A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25:14-5.
84. Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001;108:619-23.
85. Cremonesi L, Forni GL, Soriani N, et al. Genetic and clinical heterogeneity of ferroportin disease. Br J Haematol 2005;131:663-70.
86. Barton JC, Edwards CQ, Phatak PD, et al. Handbook of Iron Overload Disorders. In: Barton JC, Edwards CQ, Phatak PD, et al, editors. Cambridge, England: Cambridge University Press; 2010.
87. Anderson G, McLaren GD. Iron physiology and pathophysiology in humans. In: Anderson G, McLaren GD, editors. New York, New York: Human Press/Springer; 2011.
88. Lanzara C, Roetto A, Daraio F, et al. Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood 2004;103: 4317-21.
89. Lee PL, Beutler E, Rao SV, et al. Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. Blood 2004;103:4669-71.
90. Rivard SR, Mura C, Simard H, et al. Clinical and molecular aspects of juvenile hemochromatosis in Saguenay-Lac-Saint-Jean (Quebec, Canada). Blood Cells Mol Dis 2000;26:10-4.
91. Janosi A, Andrikovics H, Vas K, et al. Homozygosity for a novel nonsense mutation (G66X) of the HJV gene causes severe juvenile hemochromatosis with fatal cardiomyopathy. Blood 2005;105:432.
92. Cazzola M, Cerani P, Rovati A, et al. Juvenile genetic hemochromatosis is clinically and genetically distinct from the classical HLArelated disorder. Blood 1998;92:2979-81.
93. Bezwoda WR, Disler PB, Lynch SR, et al. Patterns of food iron absorption in iron-deficient white and indian subjects and in venesected haemochromatotic patients. Br J Haematol 1976;33:425-36.
94. Milder MS, Cook JD, Finch CA. Influence of food iron absorption on the plasma iron level in idiopathic hemochromatosis. Acta Haematol 1978;60:65-75.
95. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3.
96. Njajou OT, Vaessen N, Joosse M, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001;28:213-4.
97. De Domenico I, Ward DM, Nemeth E, et al. The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci U S A 2005; 102:8955-60.
98. Sham RL, Phatak PD, West C, et al. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis 2005;34: 157-61.
99. Barton JC, Acton RT, Lee PL, et al. SLC40A1 Q248H allele frequencies and Q248H-associated risk of non-HFE iron overload in persons of sub-Saharan African descent. Blood Cells Mol Dis 2007; 39:206-11.
100. Whitlock EP, Garlitz BA, Harris EL, et al. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2006;145:209-23.
101. Barton JC, Rothenberg BE, Bertoli LF, et al. Diagnosis of hemochromatosis in family members of probands: a comparison of phenotyping and HFE genotyping. Genet Med 1999;1:89-93.